AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05320822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Return to Activity (Group 1)
Description: Participant will be asked to use symptoms to guide activity from the time of the injury until participant is asymptomatic. Once asymptomatic, participant will begin the PRA TBICoE clinical recommendation. During this time clinicians will document activities in each stage in addition to initial symptom checklist, stage of PRA CoE progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
Study NCT06124144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleylphosphocholine
Description: The trial is a dose escalation trial that follows a 3+3 approach. The sample size is determined by a decision-making algorithm and by the tolerability of the study drug in the study participants. This design follows predetermined rules that help identify notable toxicities in time with a reasonable degree of accuracy. The initial dose will be 50mg OlPC (1 capsule) and participants in subsequent cohorts will receive 100mg (2 capsules), 150mg (3 capsules), 200mg (4 capsules), 250mg (5 capsules), or 300mg (6 capsules) if the previous doses are tolerated. The study ends when the last cohort is completed or when it is determined that a dose (within a cohort) is not tolerable.
Study NCT05241496 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration
Description: Lidocaine in spray form is a simple and convenient local anaesthetic with minimal adverse effects and is often used in dentistry for oral mucosal anaesthesia during minor surgical interventions. The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration. Lidocaine acts by stabilization of the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action (Hüseyin Aksoy et al. ,2016 ) .
Study NCT03981211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
Description: 8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily
Study NCT03981211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
Description: 4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily
Study NCT04887714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mask
Description: Mask wearing
Study NCT05508191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO₂ Laser
Description: Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. Half of the face will be irradiated with AMIⓇ fractional CO₂ laser according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
Study NCT05508191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. The other half of the face will be treated with DrPenⓇ dermapen according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
Study NCT04974346 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation
Description: The para-aortic area, from left renal vein level to abdominal aorta bifurcation level，will be prophylactic irradiation. The other intervention is the same as control arm.
Study NCT05505214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacterial decolonization
Description: Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT.
Study NCT05505214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% cream
Description: Mometasone furoate 0.1% cream to be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
Study NCT05505214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacterial decolonization and Mometasone furoate 0.1% cream
Description: Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT. Also, mometasone furoate 0.1% cream will be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
Study NCT05615012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days
Study NCT05615012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Specified dose on specified days
Study NCT05615012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Specified dose on specified days
Study NCT05615012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Specified dose on specified days
Study NCT05615012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Specified dose on specified days
Study NCT05615012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days
Study NCT05109650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: IV infusions
Study NCT05109650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: Ⅳ infusions
Study NCT04974346 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic definitive concurrent chemoradiation
Description: Pelvic definitive concurrent chemoradiation, including external beam radiotherapy, concurrent chemotherapy and brachytherapy.
Study NCT06412705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction, guided bone regeneration and dental implant
Description: The arm received tooth extraction and contextual guided bone regeneration. After 4 months, a dental implant was inserted.
Study NCT06108336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMS during sequence-demanding task
Description: TMS is administered during the execution of sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
Study NCT06108336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMS during sequence-demanding task
Description: TMS is administered during the execution of sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
Study NCT06108336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No TMS during sequence-demanding task
Description: TMS is not administered during the execution of sequence-demanding task.
Study NCT06108336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No TMS during sequence-demanding task
Description: TMS is not administered during the execution of sequence-demanding task.
Study NCT06108336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMS during non-sequence-demanding task
Description: TMS is administered during the execution of non-sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
Study NCT06108336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMS during non-sequence-demanding task
Description: TMS is administered during the execution of non-sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
Study NCT04890938 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sputum-guided management and comprehensive care management
Description: Those in the intervention group will have their treatment determined by the presence and type of airway inflammation whether during AECOPD or as part of clinic optimization. Corticosteroids are given for airway eosinophilia (sputum eosinophils >3%), and antibiotics for airway neutrophilia (sputum neutrophils ≥65% and total cells >10 million cells/gram) or a positive sputum culture. Specialized stains to identify aspiration (Oil Red O; (3)) and left ventricular dysfunction (Perl's Prussian blue; (4)) will guide swallowing assessment and cardiac work-up, respectively. If a sputum sample is not produced as an outpatient spontaneously, then sputum induction will be pursued 8 weeks after discharge. If there are no sputum samples to guide inhaler regimen, then it will be determined by the study physician guided by the Canadian Thoracic Society guidelines (2) if a sputum-guided regimen has not already been established.
Study NCT04890938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: As per previous, this group will receive three follow-up visits with study pulmonologist and clinic personnel interventions.
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/paracetamol
Description: Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
Study NCT06476769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blow bottle technique
Description: There were 20 patients in group A received blow bottle device and postural drainage for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
Study NCT06476769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: percussion
Description: Group B: There were 20 patients in group B received postural drainage with percussion for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
Study NCT06489353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-watching
Description: Participants will watch age-appropriate and engaging videos.
Study NCT06489353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blowing Pinwheels
Description: Participants will blow pinwheels during the venipuncture procedure
Study NCT04745156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNS System Implantation
Description: Following resection consistent with SoC, if there is evidence of residual tumor which cannot be resected due to invasion of hand-M1 but which is small enough to be covered by two four-electrode strips, these strips will be placed on the functional cortex of interest and secured to the dura. The location of the leads will be registered into the navigation software (either Medtronic Stealth or Brainlab). The dura will then be closed as watertight as possible, and the RNS System will be incorporated into the craniotomy on closure Prior to closure, four bone screws will be placed and registered to the intraoperative navigation system as internal fiducials to be retrieved for future procedures.
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen/paracetamol
Description: Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (HCl)
Description: Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine hydrochloride (HCl)
Description: Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
Study NCT05039619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
Study NCT05764733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisphosphonate
Description: Medicine used to treat bone problems, called osteopenia or osteoporosis.
Study NCT05764733 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training/Bone-Loading Exercise
Description: Exercise in small groups three days per week under the supervision of exercise physiologists. Heart rate and blood pressure will be measured before and after each session and participants will warm-up by walking or cycling for five minutes at a slow pace. All RT exercises will be conducted on machines which accommodate different body sizes and allow small increments in resistance, both important considerations for low functioning older adults with obesity.
Study NCT05764733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training/Bone-Loading Exercise
Description: Exercise in small groups three days per week under the supervision of exercise physiologists. Heart rate and blood pressure will be measured before and after each session and participants will warm-up by walking or cycling for five minutes at a slow pace. All RT exercises will be conducted on machines which accommodate different body sizes and allow small increments in resistance, both important considerations for low functioning older adults with obesity.
Study NCT05764733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules identical to the active alendronate capsules without any active ingredients with the same dosing and follow up as BIS treatment group.
Study NCT05493527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive high frequency oscillatory ventilation
Description: A time-cycled, pressure-limited, and continuous-flow neonatal ventilator (SLE6000; SLE) was used for neonates assigned to the NHFOV group. The settings were as follows:~1. a frequency of 10 Hertz ( range, 8-12 Hz);~2. an inspiratory time of 50% (1:1)~3. an oscillation amplitude of 35 centimeter of water column (cmH2O) (subsequent regulation range, 20-40 cmH2O) Oscillation amplitude would be regulated according to the level of carbon dioxide(CO2). Visible chest oscillation was not necessary because elimination of CO2 during NHFOV could also occur in the upper respiratory airway dead space~4. Mean airway pressure (MAP) of 10 cm H2O ( range, 7-15) MAP was regulated according to an open lung recruitment strategy~5. fraction of inspired oxygen (FIO2) regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter.
Study NCT05493527 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive positive pressure ventilation
Description: NIPPV will be delivered by ventilator generating the targeted pressures. Infants will be on:~1. Peep ranging from 5 to 10 cmH2O,~2. Peak inspiratory pressure range 15-25 cmH2O~3. Rate range 40-50 breath/minute~4. FIO2 regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter.
Study NCT06108336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No TMS during non-sequence-demanding task
Description: TMS is not administered during the execution of non-sequence-demanding task
Study NCT06108336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No TMS during non-sequence-demanding task
Description: TMS is not administered during the execution of non-sequence-demanding task
Study NCT05263986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1.
Study NCT06421636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Administered subcutaneous (SC)
Study NCT05097651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution
Description: Cannabidiol 100mg/mL in a sesame seed oil, strawberry flavored solution, taken orally at bedtime in self-titrated dose between 50mg and 600mg. Once a dose that results in relief of symptoms is reached, it will remain as the maintenance dose, not to exceed 600mg.
Study NCT05097651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert sesame seed oil
Description: Placebo will be identical strawberry flavored sesame seed oil-based solution without CBD.
Study NCT05093673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal Cerebellar tDCS
Description: 2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes.
Study NCT05093673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semantic Feature Analysis (SFA)
Description: Semantic Feature Analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The treatment will proceed according to a series of steps including naming aloud the target picture, generating semantic features, naming aloud the target picture again, and generating a sentence using the target word.
Study NCT05093673 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Semantic Feature Analysis (SFA)
Description: Semantic Feature Analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The treatment will proceed according to a series of steps including naming aloud the target picture, generating semantic features, naming aloud the target picture again, and generating a sentence using the target word.